Zelira Therapeutics (ASX:ZLD) 3-Year Revenue Growth Rate : -50.30% (As of Jun. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics 3-Year Revenue Growth Rate?

Zelira Therapeutics's Revenue per Share for the six months ended in Jun. 2024 was A$0.00.

During the past 12 months, Zelira Therapeutics's average Revenue per Share Growth Rate was -73.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -50.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Zelira Therapeutics was 176.10% per year. The lowest was -97.90% per year. And the median was -50.30% per year.

Competitive Comparison of Zelira Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Zelira Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's 3-Year Revenue Growth Rate falls into.

Zelira Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Zelira Therapeutics (ASX:ZLD) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Zelira Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zelira Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ZLDAF:USA G1G:Germany

Address

101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website

https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics Headlines

No Headlines